In initial studies, agonistic 4-1BB antibodies showed antitumor effects by activating both CD4+ and CD8+ T cells in sarcoma mouse models and increased CD8+ TILs in pancreatic cancer [15,16]. This evidence concerns the gene CD8A and sarcoma.